30 mar: Aktieetilbagekøbsprogram i SP Group A/S
30 mar: Børsmeddelelse nr. 20.2017 Indkaldelse til ordinær generalforsaml..
30-03-2017 13:09:12

Lundbeck held its Annual General Meeting on 30 March 2017 at the company’s registered office

Relateret indhold
21 apr - 
Aktier/middag: Pandora og Mærsk dykker i afventende rød..
19 apr - 
Onsdagens aktier: Pandora endte i front for forårsgrønt..
19 apr - 
Aktier/middag: Pandora kommer lidt igen i forårsstemt C..
Relateret debat
01 mar - 
Mener du stadigvæk, at din analyse er korrekt? Ov..
28 feb - 
Se den tekniske analyse her.
23 feb - 
Ja og det tog dig ikke mere end en måned at opdag..

Valby, Denmark, 2017-03-30 13:09 CEST (GLOBE NEWSWIRE) --

Valby, Denmark, 30 March 2017 - H. Lundbeck A/S (Lundbeck) today announced that at the Annual General Meeting the report by the Board of Directors was adopted and the annual report was approved.

The proposal to distribute a dividend of 40% of the net profit for the accounting year 2016, corresponding to DKK 2.45 per share, or a total dividend of DKK 484 million, was adopted.

Lars Rasmussen, Lene Skole, Lars Holmqvist and Jesper Ovesen were re-elected to the Board of Directors. In addition, Jeremy M. Levin was elected to the Board of Directors. Terrie Curran did not stand for re-election. Immediately after the General Meeting, the Board of Directors elected Lars Rasmussen as Chairman and Lene Skole as Deputy Chairman of the Board of Directors.

The Board of Directors of Lundbeck will hereafter comprise:

  • Lars Rasmussen (Chairman)

  • Lene Skole (Deputy Chairman)

  • Lars Holmqvist

  • Jesper Ovesen

  • Jeremy M. Levin

  • Mona Elisabeth Elster (employee representative)

  • Jørn Møller Mayntzhusen (employee representative)

  • Henrik Sindal Jensen (employee representative)

 

After having elected its Chairman and Deputy Chairman, the Board of Directors appointed members for the Audit Committee, the Remuneration Committee and the Scientific Committee.

Jesper Ovesen, Lars Rasmussen and Lars Holmqvist were elected as members of the Audit Committee. Lars Rasmussen and Lene Skole were elected as members of the Remuneration Committee. Jeremy M. Levin and Lene Skole were elected as members of the Scientific Committee.

The General Meeting approved the remuneration for the Board of Directors for the year 2017.

Deloitte Statsautoriseret Revisionspartnerselskab was re-elected as the company's auditor.

The proposal to give the Board of Directors authorization to let the company acquire own shares of a total nominal value of up to 10% of the share capital was adopted.

The Chairman of the General Meeting was authorised to file for registration the resolutions passed at the general meeting with the Danish Business Authority.

No other business was on the agenda at the Annual General Meeting.

The Board of Directors

 

Lundbeck contacts

Investors:

Media:

 

 

Palle Holm Olesen

Mads Kronborg

Vice President,  Investor Relations

Senior Director, Corp. Communication

palo@lundbeck.com

mavk@lundbeck.com

+45 30 83 24 26

+45 36 43 40 00

 

About H. Lundbeck A/S

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are Alzheimer's disease, depression, Parkinson's disease and schizophrenia.

Our approximately 5,000 employees in 55 countries are engaged in the entire value chain throughout research, development, manufacturing, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have production facilities in Denmark, France and Italy. Lundbeck generated revenue of DKK 15.6 billion in 2016 (EUR 2.1 billion; USD 2.2 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck.

 

Safe Harbor/Forward-Looking Statements

The above information contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made taking into account past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.

Vedhæftet fil: UK_PDF.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Coloplast: Amerikansk rival solgt for 164 mia. kr.

24-04-2017 08:18:20
Det amerikanske medicoselskab C.R. Bard, der er en stor konkurrent til danske Coloplast på markedet for katetre og urologi, er på vej til at blive solgt til Beckton, Dickinson and Company (BD) for hele 24 mia. dollar - svarende til godt 164 mia. kr.BD betaler 317 dollar per aktie for C.R. Bard, hvilket svarer til en præmie på 25,3 pct. sammenlignet med lukkeniveauet fredag på 253,07 dollar.Aftalen..

Mærsk: Rater ud af Europa til Asien skyder markant i vejret

21-04-2017 16:24:34
Mens fragtraterne fra Asien til Europa i denne uge har udviklet sig næsten fladt, så er spotraterne den anden vej - altså ud af Europa til Asien - skudt markant i vejret.Ifølge Drewry's World Container Index steg spotraterne fra Europa til Asien i denne uge med 10 pct. til et hidtil uset højt niveau, skriver Journal Of Commerce.De seneste efterhånden mange ugers ratefremgang på den trafik skyldes ..

Vestas fik klart flere ordrer end konkurrenterne i første kvartal

21-04-2017 13:41:33
Vestas var i første kvartal topscorer blandt de store vindmølleproducenter på antallet af annoncerede faste og ubetingede ordrer.I alt havde Vestas' ordrer en samlet kapacitet på 1,3 gigawatt (GW), og det var dermed en del bedre end Gamesa på andenpladsen, der annoncerede ordrer på samlet 0,8 GW, skriver Bloomberg Intelligence.Vestas' ordreindgang var 25 pct. lavere end i samme kvartal året før, m..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Udsigt til positiv åbning - måske med rekord
2
Frankrig/Danske: Valgresultat er godt nyt for aktiemarkedet
3
Jysk energigigant taber over en millard på Stofa - citat
4
Coloplast: Amerikansk rival solgt for 164 mia. kr.
5
Frankrig/økonomer: Valgresultat får investorer til at ånde lettet op

Relaterede aktiekurser

Lundbeck A/S 345,40 1,1% Stigning i aktiekurs
H.Lundbeck A/S DKK5 49,54 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. april 2017 09:33:00
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170403.1 - EUROWEB2 - 2017-04-24 09:33:00 - 2017-04-24 09:33:00 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x